2023 Prostate Cancer Facts & Statistics

Nationwide Incidence Rate

1 in 8 men will be diagnosed during his lifetime
3.1M men currently diagnosed

This year in the United States...

New cases: 288,300
Deaths: 34,700
Veterans are 1.5x more likely to get prostate cancer.
African-American men are 2.1x more likely to die of prostate cancer.

Incidence Rate in New Jersey

140.1 in every 100,000 men diagnosed
16.7 in every 100,000 men die from the disease

This year in New Jersey...

New cases: 9460
Deaths: 730

Veterans are 1.5x more likely to get prostate cancer.
African-American men are 2.1x more likely to die of prostate cancer.

National Rankings by State:

#1 for prostate cancer incidence
#49 for prostate cancer deaths

Source: Estimates based on 2023 data from the American Cancer Society

ZERO’s Impact in New Jersey

Patient Programs

- ZERO360 is ZERO’s comprehensive patient navigation service that provides individualized case management to help patients and their families connect with financial assistance, navigate insurance, and find other kinds of support including emotional support and even transportation assistance.
- ZERO also offers peer-to-peer support through our Us TOO Support Groups and MENtor programs. We match patients and caregivers with someone who has been on a similar journey to provide ongoing, one-on-one support. We also run a nationwide network of support groups for those affected by prostate cancer.
- ZERO Connect is our online private Facebook support group where you can connect with others affected by prostate cancer, learn from their experiences, and ask questions to patients and loved ones across the country.

ZERO Prostate Cancer is the leading national nonprofit with the mission to end prostate cancer and help all who are impacted. ZERO advances research, provides support, and creates solutions to achieve health equity to meet the most critical needs of our community. Visit our website: www.zerocancer.org

ZERO Contact:
Ali Manson, MPH
Vice President, Government Relations & Advocacy
ali@zerocancer.org | 202-888-9401
CDMRP Grants in New Jersey

Year Introduced: 1997  
Total Grants to Date: 36  
Total Grand Awards Through FY 2021*: $14.7M

*PCRP data for FY 2022 has not yet been posted

<table>
<thead>
<tr>
<th>Grant Recipient</th>
<th>Year</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rutgers University</td>
<td>2008</td>
<td>$1560000</td>
</tr>
<tr>
<td>Rutgers University</td>
<td>2021</td>
<td>$1177437</td>
</tr>
<tr>
<td>Rutgers University</td>
<td>2016</td>
<td>$954000</td>
</tr>
<tr>
<td>Rutgers University</td>
<td>2009</td>
<td>$849545</td>
</tr>
<tr>
<td>Rutgers University</td>
<td>2009</td>
<td>$690962</td>
</tr>
</tbody>
</table>

CDC’s National Comprehensive Cancer Control Program (NCCCP) Funding in New Jersey:

- Goal: Reduce the age-adjusted death rate of males from prostate cancer per 100,000 to 23.0 for total males, 23.0 for white males, and 46.0 for black males, ensuring that all efforts are appropriate culturally, linguistically, and at the proper literacy level, by 2010.

- Goal: To promote a public health message regarding prostate cancer screening and the benefits and risks of early detection, symptoms, and follow-up for normal and abnormal screening and treatment.

- Objective: To increase public knowledge among all people about the risk factors associated with prostate cancer and the benefits of early detection, especially for men aged 40 years and older who are at high risk, men of African descent, and men with a family history of prostate cancer.

- Strategy: Promote educational programs that comprehensively describe prostate cancer screening, the risks involved in screening, symptoms, follow-up, and treatment for all men, including participation in clinical trials.

- Strategy: Promote educational programs that describe the issues related to barriers, myths, access, funding for prostate cancer screening, follow-up, and treatment for high-risk individuals throughout the age...
continuum, especially men of African descent. Promote the provision of these educational programs by partnering with national, local, and statewide organizations.

• Strategy: Identify and partner with community-based organizations for prostate cancer educational programs to further implementation.

• Strategy: Develop and distribute a prostate cancer resource guide for New Jersey residents, as well as a communication plan for public education on prostate cancer.

• Goal: To improve client/patient education about prostate cancer GOAL PR-2 screening, risk factors, symptoms, follow-up, and treatment.

• Objective: To increase knowledge among men with normal screening results about the need to annually discuss prostate cancer screening, using nationally recognized screening guidelines, with a medical professional.

• Strategy: Promote educational materials and resources that provide information on prostate health and screening.

• Strategy: Ensure that distributed materials on prostate health and screening are up to date.

• Strategy: Develop a communication plan for client/patient education on prostate cancer.

• Objective: To increase knowledge among men with screening abnormalities about the benefits and risks associated with nationally recognized prostate cancer diagnostic and treatment procedures by providing information and resources.

• Strategy: Investigate available prostate cancer educational materials and resources that explain in detail the next steps to be taken following an abnormal screening, the available procedures, and the benefits and risks of each procedure. Develop these materials if needed.

• Strategy: Distribute the above-mentioned materials to men with abnormal screening results for prostate cancer.

• Goal: To increase access to prostate cancer services for all New Jersey men, including education, screening, treatment, and palliative care.

• Objective: To increase the number of contacts, e.g., prostate cancer screenings, education, support groups, etc. made available by healthcare practitioners and advocates for targeted populations.

• Strategy: Partner with community leaders/community-based organizations, including faith-based organizations, on prostate cancer education and screening programs to create incentives that attract underserved populations.

ZERO Prostate Cancer is the leading national nonprofit with the mission to end prostate cancer and help all who are impacted. ZERO advances research, provides support, and creates solutions to achieve health equity to meet the most critical needs of our community. Visit our website: www.zerocancer.org

ZERO Contact:
Ali Manson, MPH
Vice President, Government Relations & Advocacy
ali@zerocancer.org | 202-888-9401
• Strategy: Identify underserved populations in need of prostate cancer education and screening using credible data available through local, state, and federal agencies.

• Strategy: Identify prostate cancer education and screening services in convenient sites or areas within communities.

• Strategy: Develop strategies to empower significant others to encourage males to seek prostate cancer education and screening services.

• Strategy: Provide advocacy services to help clients with prostate cancer navigate the healthcare system.

• Strategy: Develop strategies to encourage payers to support community-based prostate cancer prevention services since early detection may be more cost effective.

• Strategy: Partner with community-based organizations to address language, education, literacy, cultural, and economic barriers to receipt of prostate cancer education and screening services.

• Strategy: Partner with community-based organizations to develop and offer culturally relevant programs located within easily accessible community sites, e.g., take prostate cancer education and screening programs to community events, bring programs to the people.

• Strategy: Evaluate funding sources through government agencies, insurance and pharmaceutical companies, and foundations to assist in finding ways to increase access to prostate cancer education and screening services.

• Goal: To expand a research agenda specific to prostate cancer issues in New Jersey.

• Objective: To develop a plan to incorporate men, in demographic groups that are underrepresented, in prostate cancer screening and clinical trials.

• Objective: To facilitate collaboration between institutions providing prostate cancer clinical trials and underrepresented populations.

• Goal: To ensure that New Jersey residents and physicians remain up to date on currently available prostate cancer technologies and resources.

• Objective: To continue to monitor and disseminate current advances in prostate cancer prevention, screening, diagnosis, and treatment.

• Objective: To continue to monitor trends in prostate cancer incidence, mortality, and survival.